Outlook Therapeutics (OTLK) Other Accumulated Expenses (2018 - 2026)

Outlook Therapeutics (OTLK) has 9 years of Other Accumulated Expenses data on file, last reported at $191542.0 in Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $191542.0, down 40.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $191542.0 (down 40.0% YoY), and the FY2025 annual result was $1.2 million, up 209.14% from the prior year.
• Other Accumulated Expenses declined to $191542.0 in Q1 2026 per OTLK's latest filing, from $359055.0 in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $5.3 million in Q2 2023 and troughed at $63220.0 in Q4 2024.
• A 5-year average of $1.1 million and a median of $544562.0 in 2024 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2023 and 2024: Other Accumulated Expenses soared 2385.81% in 2023, then slumped 96.13% in 2024.
• A 5-year view of Other Accumulated Expenses shows it stood at $1.2 million in 2022, then soared by 32.21% to $1.6 million in 2023, then tumbled by 96.13% to $63220.0 in 2024, then soared by 467.95% to $359055.0 in 2025, then sank by 46.65% to $191542.0 in 2026.
• Business Quant data shows OTLK's Other Accumulated Expenses at $191542.0 in Q1 2026, $359055.0 in Q4 2025, and $1.2 million in Q3 2025.